You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
TOPIC 319 PHASE I; RECOMBINANT RABBIT MONOCLONAL ANTIBODIES AS AFFINITY CAPTURES
SBC: AVANTGEN INC Topic: NCIRecombinant rabbit monoclonal antibodies as affinity captures for peptides PUBLIC HEALTH RELEVANCE
SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Discovery of novel Alzheimer's Disease-specific antigens/epitopes and their captu
SBC: AVANTGEN INC Topic: NIADESCRIPTION (provided by applicant): Since substantial neuronal loss has already occurred by the time Alzheimer's Disease (AD) manifests clinically, considerable research has been directed towards developing biomarkers for the reliable diagnosis of mild ADand the prodromal stage of mild cognitive impairment. The best studied biomarkers, A1-42 peptide and tau/P-tau, can distinguish cohorts of ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Novel platform for isolation of rabbit monoclonal antibodies against modified RNA bases
SBC: AVANTGEN INC Topic: NIDADESCRIPTION (provided by applicant): RNA editing and post-transcriptional modification is emerging as a key epigenetic mechanism for fine tuning genetic diversity and RNA function of particular importance in the brain. However, while some RNA editing processes have been relatively well described, other RNA modifications are poorly understood and many questions remain about the true significance of ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
IGF OT IGF RECOMBINANT RABBIT MONOCLONAL ANTIBODIES AS AFFINITY CAPTURES FOR PEPTIDES
SBC: AVANTGEN INC Topic: NCINot Available
SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Developing a highly specific and sensitive glucagon ELISA kit
SBC: AVANTGEN INC Topic: 200DESCRIPTION provided by applicant With prediabetes and diabetes reaching epidemic proportions there is an urgent need to identify more effective therapeutics Diabetes is characterized by elevated levels of the peptide hormone glucagon and inappropriate suppression of glucagon during an oral glucose tolerance test Glucagon plays a major role in up regulating glucose release from the liver d ...
SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Novel approach for developing antibody reagents to probe changes in the synapse p
SBC: AVANTGEN INC Topic: NIDADESCRIPTION provided by applicant The development of addiction involves the dopaminergic reward pathway and downstream negative changes that lead to craving and repeat self administration While it is clear this process involves changes in neuronal plasticity t the synapse junction the exact changes at the protein level leading to the development of dependence and negative responses associated ...
SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
N/A
SBC: AVANTGEN INC Topic: N/ALocation 10151 Pacific Mesa Blvd. SAN DIEGO, CA 92121 United States N43DA0900023 $200 000.00 2 008 N/A Department of Health and Human Services National Institutes of Health SBIR PHS2009-1 AVANTGEN INC Phase I N43DA0900023 1 ...
SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
Topic 372: Development and Validation of Non- Mouse Reagents to Enable Preclinical Development of Novel Therapeutics
SBC: AVANTGEN INC Topic: NCIThere is an increasing appreciation that dogs with naturally occurring cancers may be a better model system for evaluating cancer therapeutics than the traditional mouse model systems. However, use of dogs for evaluating the emerging class of immunotherapeutics for oncology is limited by the availability of suitable reagents to mentor the response of the canine immune system. The majority of reage ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
TOPIC 372:DEVELOPMENT AND VALIDATION OF NON-MOUSE REAGENTS TO ENABLE PRECLINICAL DEVELOPMENT OF NOVEL THERAPEUTICS
SBC: AVANTGEN INC Topic: 372Dogs with naturally occurring cancers can serve as a better model system for evaluating novel cancer immuno-therapeutics than the traditional mouse model systems, and also provide a target patient group. However, use of canine cancer patients is currently limited by the availability of suitable reagents to monitor canine immune responses. The majority of commercially-available reagents for canine ...
SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
DEVELOPMENT OF RAPID AND POINT-OF-CARE DIAGNOSTIC KIT FOR HEPATITIS C VIRUS DETECTION
SBC: AVANTGEN INC Topic: 99To develop rapid, point of care diagnostics for Hepatitis C virus.
SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health